230 related articles for article (PubMed ID: 12831061)
1. A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth.
Arakelyan L; Vainstein V; Agur Z
Angiogenesis; 2002; 5(3):203-14. PubMed ID: 12831061
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.
Fujiyama S; Matsubara H; Nozawa Y; Maruyama K; Mori Y; Tsutsumi Y; Masaki H; Uchiyama Y; Koyama Y; Nose A; Iba O; Tateishi E; Ogata N; Jyo N; Higashiyama S; Iwasaka T
Circ Res; 2001 Jan; 88(1):22-9. PubMed ID: 11139469
[TBL] [Abstract][Full Text] [Related]
3. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
[TBL] [Abstract][Full Text] [Related]
4. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.
Holash J; Wiegand SJ; Yancopoulos GD
Oncogene; 1999 Sep; 18(38):5356-62. PubMed ID: 10498889
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
6. Vascular phenotype identification and anti-angiogenic treatment recommendation: A pseudo-multiscale mathematical model of angiogenesis.
Hutchinson LG; Gaffney EA; Maini PK; Wagg J; Phipps A; Byrne HM
J Theor Biol; 2016 Jun; 398():162-80. PubMed ID: 26987523
[TBL] [Abstract][Full Text] [Related]
7. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor and anti-angiogenic peptides as therapeutic and investigational molecules.
Zachary I
IDrugs; 2003 Mar; 6(3):224-31. PubMed ID: 12789611
[TBL] [Abstract][Full Text] [Related]
9. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.
Guo P; Hu B; Gu W; Xu L; Wang D; Huang HJ; Cavenee WK; Cheng SY
Am J Pathol; 2003 Apr; 162(4):1083-93. PubMed ID: 12651601
[TBL] [Abstract][Full Text] [Related]
11. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
12. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization.
Asahara T; Chen D; Takahashi T; Fujikawa K; Kearney M; Magner M; Yancopoulos GD; Isner JM
Circ Res; 1998 Aug; 83(3):233-40. PubMed ID: 9710115
[TBL] [Abstract][Full Text] [Related]
13. [Neoplasms and angiogenesis].
Lewy-Trenda I
Pol Merkur Lekarski; 2002 Sep; 13(75):225-8. PubMed ID: 12474576
[TBL] [Abstract][Full Text] [Related]
14. [Angiogenesis, anti-angiogenesis, and tumor suppression].
Shibuya M
Nihon Yakurigaku Zasshi; 2002 Nov; 120(5):285-94. PubMed ID: 12491804
[TBL] [Abstract][Full Text] [Related]
15. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth.
Hawighorst T; Skobe M; Streit M; Hong YK; Velasco P; Brown LF; Riccardi L; Lange-Asschenfeldt B; Detmar M
Am J Pathol; 2002 Apr; 160(4):1381-92. PubMed ID: 11943723
[TBL] [Abstract][Full Text] [Related]
16. Localization of mRNA for vascular endothelial growth factor (VEGF), angiopoietins and their receptors during the peri-implantation period and early pregnancy in marmosets (Callithrix jacchus).
Rowe AJ; Wulff C; Fraser HM
Reproduction; 2003 Aug; 126(2):227-38. PubMed ID: 12887279
[TBL] [Abstract][Full Text] [Related]
17. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis.
Goede V; Schmidt T; Kimmina S; Kozian D; Augustin HG
Lab Invest; 1998 Nov; 78(11):1385-94. PubMed ID: 9840613
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitation of tumor angiogenesis, growth and metastasis by blocking VEGF paracrine pathway].
Wang F; Tian YH; Li L; Chen XF; Hu HH; Li CY; Huang Q
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2002 Mar; 34(2):165-70. PubMed ID: 12006990
[TBL] [Abstract][Full Text] [Related]
19. Promises and pitfalls of anti-angiogenic therapy in clinical trials.
McCarty MF; Liu W; Fan F; Parikh A; Reimuth N; Stoeltzing O; Ellis LM
Trends Mol Med; 2003 Feb; 9(2):53-8. PubMed ID: 12615038
[TBL] [Abstract][Full Text] [Related]
20. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
